Multi-target modulation of the homologous recombination pathway by resveratrol promotes DNA damage repair in POI: integrated network pharmacology, molecular dynamics simulation, and experimental validation

Zhaoyang Yu, Weilong Peng, Mujun Li, Feiwen Li, Tao Zhang, Yingqi Nong, Chang Liu, Wenjuan Liu, Hongfan Ding, Xiaoyin Lv, Jiao Wang, Xiqian Zhang, F Liu, Huimei WuInternational Journal of Surgery 2026 · DOI

TL;DR

This study reveals how resveratrol (RSV), a natural compound, protects against premature ovarian insufficiency (POI) by enhancing DNA repair. Using a multi-pronged approach combining computational modeling and lab experiments, the researchers identified key DNA repair proteins (ATM, BRCA1, RAD51) as RSV targets and demonstrated RSV's ability to activate the homologous recombination (HR) pathway, a crucial DNA repair mechanism.

What Problem Does This Paper Address?

Premature ovarian insufficiency (POI) is a condition where ovaries cease functioning before age 40, leading to infertility and early menopause. Current treatments like hormone replacement therapy have limitations and potential risks. Resveratrol (RSV) has shown promise in improving reproductive health, but its precise molecular targets and mechanisms in POI have remained unclear. This paper aims to bridge this knowledge gap by elucidating how RSV might protect ovarian function at a molecular level, specifically focusing on DNA damage repair.

Methods

The researchers employed a sophisticated, multi-disciplinary approach:

  • Network Pharmacology: This computational technique was used to identify overlapping molecular targets between RSV and POI. It involved analyzing vast biological databases to predict potential drug-target and disease-gene interactions.
  • Gene Ontology (GO) and KEGG Enrichment Analysis: These analyses helped understand the biological functions and signaling pathways associated with the identified overlapping targets.
  • Protein-Protein Interaction (PPI) Network Construction: This method mapped how the identified target proteins interact with each other, helping to pinpoint crucial "hub" genes.
  • Molecular Docking: This computational technique simulated how RSV binds to the identified target proteins at an atomic level, predicting binding affinity and stability.
  • Molecular Dynamics (MD) Simulations: These simulations extended the docking analysis by observing the dynamic behavior of the protein-RSV complexes over time (100 ns), assessing their stability and conformational changes under near-physiological conditions.
  • Experimental Validation:
    • In vivo: A rat model of POI was created using cyclophosphamide (CTX) to mimic chemotherapy-induced ovarian damage. The protective effects of RSV were then assessed by examining ovarian morphology and hormone levels.
  • In vitro: A human granulosa cell line (KGN) was used to create a POI model. RSV's effects on DNA damage and homologous recombination (HR) were evaluated using TUNEL staining, Western blotting, and immunofluorescence. The role of RAD51 was specifically tested using a RAD51 inhibitor.

Datasets

  • Drug-Target Databases: SwissTargetPrediction, Super-PRED, SEA, HIT, and CTD were used to identify RSV-related targets.
  • Disease-Target Databases: GeneCards, DisGeNET, and OMIM were used to identify POI-related genes.
  • miRNA-mRNA-TF Databases: ENCORI and TRRUST were used for predicting regulatory relationships.
  • Protein Structure Databases: RCSB PDB was used for obtaining protein structures for docking.
  • RSV Structure Database: PubChem was used for obtaining the 3D structure of RSV.

No new benchmarks were introduced; existing public databases were utilized.

Key Insights and Ideas

  • RSV Targets Key DNA Repair Proteins: The study pinpointed ATM, BRCA1, and RAD51 as crucial targets of RSV in the context of POI. These proteins are central to the homologous recombination (HR) pathway, a vital mechanism for repairing DNA double-strand breaks.
  • HR Pathway is Central to RSV's Protective Effect: The research strongly suggests that RSV's therapeutic benefits in POI are mediated by its ability to enhance the HR pathway's function, thereby promoting DNA repair.
  • Computational Modeling Predicts Stability: Molecular docking and MD simulations provided strong evidence for RSV's stable binding to ATM, BRCA1, and RAD51, offering a structural basis for its multi-target action. The RAD51-RSV complex showed particularly high stability.
  • RSV Restores Ovarian Function: In vivo experiments in a rat model confirmed that RSV treatment partially reversed CTX-induced ovarian damage, improving follicle counts and AMH levels.
  • RSV Activates DNA Repair in Granulosa Cells: In vitro experiments demonstrated that RSV not only reduced DNA damage (via TUNEL assay) but also upregulated RAD51 and downregulated yH2AX (a marker of DNA damage), indicating enhanced DNA repair. This effect was dependent on RAD51 activity.

Key Results

  • 609 Overlapping Genes: Identified 609 genes that are targets of both RSV and implicated in POI.
  • Three Core Hub Genes: ATM, BRCA1, and RAD51 were identified as the most critical hub genes within the HR pathway.
  • Strong Binding Affinity: Molecular docking showed significant binding energies for RSV with ATM (-6.9 kcal/mol), BRCA1 (-6.1 kcal/mol), and RAD51 (-6.5 kcal/mol).
  • Stable Protein-RSV Complexes: MD simulations confirmed the stable interactions of RSV with these three proteins over 100 ns.
  • Improved Ovarian Morphology in Rats: RSV treatment partially restored ovarian morphology and increased secondary follicle counts in CTX-induced POI rats.
  • Increased AMH Levels in Rats: Serum AMH levels were significantly increased in RSV-treated POI rats.
  • Reduced DNA Damage in Cell Models: RSV treatment significantly reduced TUNEL-positive cells (indicating DNA damage) in 4-HC-induced POI granulosa cells.
  • Upregulated RAD51 and Downregulated yH2AX: Western blot analysis showed RSV increased RAD51 and decreased yH2AX expression in POI cells.
  • RAD51 Inhibition Abolished RSV's Effect: The protective effect of RSV was reversed when a RAD51 inhibitor (RI-1) was used, confirming RAD51's crucial role.

Limitations and Future Work

  • Limitations of Molecular Docking: The authors acknowledge that molecular docking provides static snapshots and may not fully capture the dynamic conformational flexibility of proteins, potentially limiting binding mode prediction accuracy.
  • Animal Model vs. Human POI: While CTX-induced POI models are standard, they may not fully replicate the complexity and heterogeneity of human POI. Extrapolating findings from rat models and cell lines to human physiology requires caution.
  • RSV Dosage and Pharmacokinetics: The chosen RSV dosage and administration route might not be optimal for pharmacokinetic conditions, potentially explaining modest changes in some target proteins. The study notes RSV's low oral bioavailability (19.07%) and poor blood-brain barrier penetration, suggesting the need for improved drug delivery systems.
  • Future Directions:
    • Longer-timescale MD simulations.
  • Site-directed mutagenesis and gene manipulation approaches.
  • Validation in additional animal and human-derived cellular models.
  • Further investigation into the upstream regulators (miRNAs and TFs) of ATM, BRCA1, and RAD51.
  • Exploring the potential of RSV as a therapeutic candidate for POI, possibly with enhanced delivery systems.

Summary updated

Abstract

This study provides structural and experimental evidence for the target selection, structural optimization, and molecular mechanism of RSV in the treatment of POI.
BibTeX
@article{yu2026multi,
  author = {Zhaoyang Yu and Weilong Peng and Mujun Li and Feiwen Li and Tao Zhang and Yingqi Nong and Chang Liu and Wenjuan Liu and Hongfan Ding and Xiaoyin Lv and Jiao Wang and Xiqian Zhang and F Liu and Huimei Wu},
  title = {{Multi-target modulation of the homologous recombination pathway by resveratrol promotes DNA damage repair in POI: integrated network pharmacology, molecular dynamics simulation, and experimental validation}},
  journal = {International Journal of Surgery},
  year = {2026},
  doi = {10.1097/js9.0000000000004655},
}
Figure